When we do things like quantum calculations, we look at the confirmer space. So what that does is give us insight into how a ...

In particular, Konagurthu says, AI/ML can help sift through a field of drug candidates in which the percentage that are ...

The CNPV program aims to reduce drug review times to 1-2 months, raising concerns about safety and regulatory scrutiny. Critics argue that accelerated timelines may lead to safety issues and strain ...

In September 2025, the European Commission (EC), together with the Heads of Medicines Agencies (HMA) and the European ...

To meet rising demand, developers of precision radiopharmaceutical therapies must overcome challenges in global isotope ...

SMA is a rare, genetic neuromuscular condition that affects people across age groups. With treatment landscapes evolving ...

Learn how a custom ADA assay was designed, incorporating acid dissociation with the ACE method to overcome drug interference using other standardized formats.

Mechanistic models and hypothesis-driven strategies generate optimized efficient solutions for drug development, says ...

Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development. Learn how a robust anti-drug antibody assay ...

Robust scale-down agitation models simulate mechanical stress essential for assessing and preventing protein aggregation in ...

Quality, stability, sustainability, and the increased and thoughtful integration of artificial intelligence are foremost in the minds of those on the leading edge of testing trends.

The FDA's CNPV program accelerates product reviews to two months for national priority products, enhancing market entry speed ...